TICKERNERD
Menu
SIONSIONHealthcare · Biotechnology

SION Stock Forecast: Sionna Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$4.90
+1.66% on the day

The 12 Wall Street analysts covering Sionna Therapeutics, Inc. hold a median 12-month price target of $6 — +22.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$214.8M
Ticker Nerd rank
30 / 100
Median analyst target
$6.00
Analysts covering
12
Revenue$0.0
Operating income−$32.5M
Net income−$29.9M
Free cash flow−$22.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.9%
1M
−32.9%
YTD
−88.1%
1Y
−82.8%
From 52W high
−90.4%
From 52W low
+8.9%
$5
$51
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SION stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Sionna Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
30 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
77
Size
66
Revisions
53
Quality
52
Issuance
43
Volatility
35
Value
29
Momentum
17
Growth
10

Accruals (77): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (10): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SION stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SION, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60$70Jan 26Apr 26Jul 26Oct 26SIONHigh $63.00Median $6.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
2 Buy10 Hold0 Sell
Low $5.00Median $6.00High $63.00

The green dot is the last close — the median target sits +22.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
15 Sept 2026WedbushMaintainsNeutral$5.00 → $6.00
11 Aug 2026GuggenheimDowngradeNeutral—
11 Aug 2026GuggenheimDowngradeNeutral—
11 Aug 2026WedbushDowngradeNeutral—
11 Aug 2026WedbushDowngradeNeutral$53 → $5.00
10 Aug 2026BTIGDowngradeNeutral—
10 Aug 2026BTIGDowngradeNeutral—
7 Aug 2026GuggenheimMaintainsBuy$50 → $60
7 Aug 2026GuggenheimMaintainsBuy—
26 May 2026CitizensReiteratesMarket Outperform—
26 May 2026CitizensReiteratesMarket Outperform$63
20 May 2026Freedom BrokerDowngradeHold—
20 May 2026Freedom BrokerDowngradeHold$38
18 May 2026StifelMaintainsBuy—
13 May 2026BTIGReiteratesBuy—
5 May 2026WedbushInitiatesOutperform—
28 Apr 2026Jones TradingMaintainsBuy—
27 Apr 2026BTIGReiteratesBuy—
3 Mar 2026GuggenheimMaintainsBuy—
2 Mar 2026BTIGReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SION appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SION vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Sionna Therapeutics, Inc. returned −82.8% against +16.2% for the S&P 500, dividends included.

SION vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150200Jan 26Apr 26Jul 26Oct 26SIONS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SION analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
5
Fundamentals

Sionna Therapeutics, Inc. (SION) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.5×

Cheaper than 87% of US stocks

Price / sales
—
Price / book
0.8×

Cheaper than 77% of US stocks

EV / EBITDA
−0.1×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−32.3%

Higher than 26% of US stocks

Return on assets
−21.5%

Higher than 18% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Sionna Therapeutics, Inc. (SION) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Sionna Therapeutics, Inc. has a market value of $214.8M and an enterprise value of $11.8M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$97.4M.

  • Diluted earnings per share, trailing twelve months: $−2.18.

  • Free cash flow in the twelve months to 30 June 2026: −$76.2M.

  • Shares outstanding: 45.2M.

  • Trailing P/E: −2.5×; forward P/E: −2.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Sionna Therapeutics, Inc. employs 59 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

SION vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SIONSionna Therapeutics, Inc.$214.8M
30
PLXProtalix Biotherapeutics, Inc.$217.5M
92
ALECAlector, Inc.$220.5M
50
PRQRProQR Therapeutics NV$216.8M
48
LYELLyell Immunopharma, Inc.$215.4M
64
GLSIGreenwich LifeSciences, Inc.$222.2M
42
TRDAEntrada Therapeutics, Inc.$214.7M
52

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Sionna Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SION news & analysis

Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference

GlobeNewsWire · 8 Oct 2026positive

Sionna Therapeutics announced presentations at the 2026 North American Cystic Fibrosis Conference, including previously disclosed post hoc SION-719 analyses supporting advancement of SION-451 plus SION-2222 into the AscenSION CF Phase 2a proof-of-concept trial. New preclinical data evaluated NBD1 stabilizers combined with other CFTR modulators across F508del genotype groups.

Why it matters — The presentations provide updates on Sionna’s clinical development plans and preclinical combination research in cystic fibrosis.

These beaten-down stocks could bounce back in January, if history is any guide

Market Watch · 21 Sept 2026neutral

Market Watch reports that tax-loss selling is likely to artificially depress 20 stocks in the fourth quarter, making them candidates to bounce back in the new year based on historical patterns. The article frames these beaten-down stocks as potential rebounds in January.

Why it matters — A Sionna Therapeutics watcher might care because, if SION is among the stocks affected by year-end tax-loss selling, the article suggests historical trends could support a January rebound in its share price.

SION to Cut Workforce by Nearly Half After CF Study Failure, Stock Down

Zacks Investment Research · 16 Sept 2026negative

Sionna Therapeutics plans to cut its workforce by 46% after its cystic fibrosis candidate SION-719 failed a key study. The company is shifting focus to its other programs, SION-451 and SION-2222.

Why it matters — SION watchers would care because the lead program's failure and a nearly half-sized workforce reduction represent a major strategic setback for the company.

Sionna Therapeutics, Inc. (SION) Discusses Post-Hoc Analysis of PreciSION CF Trial and Advancement of Dual Combination Program Transcript

Seeking Alpha · 15 Sept 2026positive

Sionna Therapeutics discussed a post-hoc analysis of its PreciSION cystic fibrosis (CF) trial and the advancement of its dual combination program in a company discussion (transcript) covered by Seeking Alpha.

Why it matters — A SION watcher would care because the post-hoc trial analysis and advancement of the dual combination program signal ongoing progress in the company's cystic fibrosis development pipeline.

Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial

GlobeNewsWire · 14 Sept 2026positive

Sionna Therapeutics announced plans to advance a dual combination of SION-451 and SION-2222 into a Phase 2a proof-of-concept trial. Post hoc analyses of the SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L, consistent with NBD1 biological activity.

Why it matters — A Sionna watcher would care because the company is advancing a promising next-stage combination therapy based on data indicating NBD1 biological activity in cystic fibrosis treatment.

FAQ

Frequently asked questions about SION stock

What is the SION stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Sionna Therapeutics, Inc. have a median 12-month price target of $6, with estimates ranging from $5 to $63. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SION stock a buy right now?

Of the 12 analysts covering Sionna Therapeutics, Inc., 2 rate it a Buy, 10 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sionna Therapeutics, Inc. 30 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SION?

As at 8 Oct 2026, Sionna Therapeutics, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (77 of 100).

Will SION stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +22.4% from the last close, and Ticker Nerd's factor model ranks Sionna Therapeutics, Inc. 30 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SION stock forecast for 2030?

No analyst covering Sionna Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SION are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $63 over the next 12 months.

How has SION stock performed over the past year?

Sionna Therapeutics, Inc. returned -82.8% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sionna Therapeutics, Inc. do?

Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for cystic fibrosis.

What is the latest news on SION?

The most recent item we track (GlobeNewsWire, 8 Oct 2026): "Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference". Sionna Therapeutics announced presentations at the 2026 North American Cystic Fibrosis Conference, including previously disclosed post hoc SION-719 analyses supporting advancement of SION-451 plus SION-2222 into the AscenSION CF Phase 2a proof-of-concept trial. New preclinical data evaluated NBD1 stabilizers combined with other CFTR modulators across F508del genotype groups.

Company

About Sionna Therapeutics, Inc.

Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for cystic fibrosis. Its current portfolio centers on small-molecule therapies designed to improve the function of the cystic fibrosis transmembrane conductance regulator, or CFTR, protein, with programs that include CFTR correctors, potentiators, and NBD1 stabilizers. The company’s work is aimed at addressing the underlying protein defects associated with cystic fibrosis, including approaches intended to work in combination with complementary modulators. Sionna Therapeutics operates as a research and development-driven organization with no commercial product portfolio disclosed in the available information. It is headquartered in Waltham, Massachusetts, and serves the biotechnology and pharmaceutical research markets through its focus on rare disease drug development.

CEO Mr. Michael Cloonan M.B.A. · 59 employees · United States · https://www.sionnatx.com